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Abstract
Background: Despite its widespread use to assess fibrosis, liver biopsy has several important drawbacks,
including that is it semi-quantitative, invasive, and limited by sampling and observer variability. Non-invasive
serum biomarkers may more accurately reflect the fibrogenetic process. To identify potential biomarkers
of fibrosis, we compared serum protein expression profiles in patients with chronic hepatitis C (CHC)
virus infection and fibrosis.
Methods: Twenty-one patients with no or mild fibrosis (METAVIR stage F0, F1) and 23 with advanced
fibrosis (F3, F4) were retrospectively identified from a pedigreed database of 1600 CHC patients. All
samples were carefully phenotyped and matched for age, gender, race, body mass index, genotype,
duration of infection, alcohol use, and viral load. Expression profiling was performed in a blinded fashion
using a 2D polyacrylamide gel electrophoresis/LC-MS/MS platform. Partial least squares discriminant
analysis and likelihood ratio statistics were used to rank individual differences in protein expression
between the 2 groups.
Results: Seven individual protein spots were identified as either significantly increased (α2-macroglobulin,
haptoglobin, albumin) or decreased (complement C-4, serum retinol binding protein, apolipoprotein A-1,
and two isoforms of apolipoprotein A-IV) with advanced fibrosis. Three individual proteins, haptoglobin,
apolipoprotein A-1, and α2-macroglobulin, are included in existing non-invasive serum marker panels.
Conclusion: Biomarkers identified through expression profiling may facilitate the development of more
accurate marker algorithms to better quantitate hepatic fibrosis and monitor disease progression.
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Background
Hepatic fibrosis is the final common pathway of liver
injury in most liver diseases and can lead to cirrhosis,
which is responsible for most clinical sequelae. Assess-
ment of the degree of fibrosis usually involves a liver
biopsy. Although liver biopsy has long been considered to
be the gold standard for assessing fibrosis, the procedure
is invasive, potentially associated with important compli-
cations to the patient, and provides only a semi-quantita-
tive assessment of fibrosis. Furthermore, the diagnostic
accuracy of a biopsy in the staging of fibrosis is seriously
affected by errors in sampling and intra-observer variation
[1-5].
Non-invasive biomarkers may provide a more dynamic
reflection of fibrogenesis; the identification and quantifi-
cation of such markers could lead to the development of
a non-invasive means to monitor disease progression
[6,7]. Serum biomarker panels (eg FibroTest, BioPredic-
tive, Paris, France) and transient elastography (FibroS-
can®, Echosens, Paris, France) methods have been
validated in chronic hepatitis C (CHC) patients, and
incorporated into clinical practice in many countries [8-
10]. These non-invasive measures may also provide prog-
nostic information that may be of clinical significance in
CHC patients with advanced disease [11]. However, these
methods are limited by variability among liver diseases of
other etiology, and in their ability to accurately differenti-
ate individual fibrosis stages [6]. Nevertheless, biomarkers
and other non-invasive approaches remain promising
alternatives to biopsy for monitoring disease progression
or assessing the efficacy of antifibrotic therapies.
We hypothesized that elucidating novel proteins differen-
tially expressed in carefully pedigreed patients with
advanced fibrosis versus those with minimal fibrosis
would allow development of novel assays or a profile that
could be used for accurate staging of hepatic fibrosis. We
thus analyzed protein expression levels in serum samples
from patients with liver fibrosis as a result of chronic hep-
atitis C virus infection.
Methods
Sample selection
Serum samples from 23 treatment-naïve chronic hepatitis
C patients with no or mild fibrosis (METAVIR stage F0,
F1) and 21 patients with advanced fibrosis (F3, F4) (Table
1) were retrospectively identified from a large hepatitis
patient and clinical research database that includes demo-
graphic, virologic, serologic, and histologic data from
more than 1600 individuals enrolled in treatment proto-
cols since 1992. The repository was developed at the
Scripps Clinic and Research Foundation and was moved
to Duke University and continued from 2002. Patients
enrolled in the database gave informed consent for the
studies in which they participated and for the use of their
data and stored serum in future studies. Such future use
had also been approved separately by the institutional
review boards at each institution. Serum samples were
snap-frozen within 4 hours of collection and stored at -
70°C. Samples were no more than 7 years old and had
undergone a single freeze/thaw cycle. METAVIR score on
liver biopsies with at least 6 portal tracts, performed at or
near the time of serum sample collection, had been deter-
mined by 3 experienced pathologists (κ coefficient of
agreement of 0.83). Mean biopsy (± SD) length was 13.1
± 3.73 mm, and patients were matched for age, gender,
race, body mass index, genotype, duration of infection,
alcohol use, alanine aminotransferase level, necroinflam-
matory activity, and serum hepatitis C viral concentra-
tions (Table 1).
Two-dimensional polyacrylamide gel electrophoresis
Frozen serum samples were thawed and centrifuged at
13,000 × g for 10 min. Albumin depletion of the superna-
tants was immediately carried out using Mimetic Blue SA
affinity chromatography (Prometic Biosciences Ltd., Cam-
bridge, UK). The depleted material was concentrated
using Vivaspin 2 (Sartorius Ltd., Epsom, UK) centrifugal
filtration devices (5000 Da MWCO) and diluted into iso-
electric focusing sample buffer (8 M urea, 4% [w/v]
CHAPS, 100 mM DTT, 0.8% carrier ampholytes pH 3–10
NL). Duplicate samples of 200 μg protein were subjected
to isoelectric focusing on 24-cm, immobilized, non-lin-
ear, pH 3–10, ReadyStrips (BioRad Laboratories, Hemel
Hempstead, UK) for 64,000 Vh using Multiphor electro-
phoresis apparatus (GE Healthcare, Little Chalfont, UK).
Focused strips were subjected to reduction and alkylation
in the presence of excess SDS using DTT and then iodoa-
cetamide, followed by SDS-PAGE on 12% (w/v) acryla-
mide slab gels (20 × 25 × 0.15 cm), essentially as
described by Görg and coworkers [12]. Proteins were
stained with SYPRO Ruby (Invitrogen Ltd., Paisley, UK),
and 16-bit digital images were acquired on FUJI FLA5000
imaging systems, employing excitation at 473 nm with a
575 nm LP filter.
Image analysis and spot selection
Individual protein features were detected, matched, and
quantified using Progenesis Discovery software (Nonlin-
ear Dynamics, Newcastle-upon-Tyne, UK). Principal
Components Analysis (PCA) [13] was carried out on the
exported dataset using Simca-P+ (Umetrics, Umea, Swe-
den), and all matched spots were ranked based on the
magnitude of expression change between the 2 groups
with mild or advanced fibrosis using partial least squares
discriminant analysis (PLS-DA) [13] and likelihood ratio
statistics [14]. The latter method is designed specifically
for proteomic data and ensures appropriate weighting is
given to the data independent of any missing values.Journal of Translational Medicine 2007, 5:33 http://www.translational-medicine.com/content/5/1/33
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Using PLS-DA, the most important protein spots were
identified using the variable important plot list.
Protein identification
Protein identifications were carried out essentially as
described previously [15]. Briefly, polyacrylamide gel
cores of protein spots with altered expression profiles
were excised using a KCore automated cutter (KBiosys-
tems, UK). The samples were then subjected to in situ
enzymatic digestion using a MassPrep liquid handling
system (Waters, UK). The digests were analysed by nanos-
cale capillary LC/MS/MS using a Waters CapLC and
Stream Select Module to deliver a flow of 5 μL/min, split
to approximately 200 nL/min. An LC Packings u-Precol-
umn, C18 PepMap 100 (Dionex, The Netherlands) guard
column trapped the peptides prior to separation on a
NAN75-15-03-C18-PM, PepMap 100 column, 75 μm ID
× 15 cm. Peptides were back-flushed from the guard col-
umn onto the analytical column at 200 nL/min and
eluted with a gradient of acetonitrile. Mass spectrometric
information was obtained using an orthogonal accelera-
tion quadrupole-Tof mass spectrometer (Q-Tof Ultima
API, Waters, UK) equipped with a Z-spray source for
nanoflow analysis and operated in V-mode. Data directed
analysis was carried out, where automatic MS/MS was
acquired on the 8 most intense, multiply charged precur-
sor ions in the m/z range 400–1500. MS/MS data were
acquired over the m/z range 50–1975. LC/MS/MS data
were then searched against an in-house non-redundant
protein database using the Mascot search engine program
(Matrix Science, UK) [16].
Results and Discussion
Data visualization by Principal Components Analysis 
(PCA)
The scores plot from the PCA analysis (Figure 1) showed
evidence of some separation between the mild and
advanced fibrosis groups in the first principal component,
which is indicative of variation in their respective protein
expression profiles. Despite the quality of this highly ped-
igreed sample set, the clustering of the 2 sample sets is not
complete, reflecting the biological variability inherent in
clinical patient cohorts.
Spot selection
Seven protein spots with altered expression levels between
mild and advanced fibrosis patients were identified (Fig-
ure 2). Compared with patients with mild fibrosis,
patients with advanced disease had increased serum
expression of 3 spots, which were identified as α2-mac-
roglobulin (A2M), haptoglobin, and a fragment of albu-
min. Conversely, the expression of 4 spots was decreased:
serum retinol binding protein (SRBP), complement C-4,
apolipoprotein A-1 (ApoA1), and 2 variants of apolipo-
protein A-IV (ApoA4). ApoA1 and SRBP were identified in
the same spot, and it was not possible to determine which
protein contributed to the alteration in intensity (Figure
2).
Table 1: Patient Demographics Based on Fibrosis Staging.
METAVIR Stage
F0-F1 F3-F4
Age (y) 43.8 ± 9.75 48.1 ± 4.18
Sex (M/F) 21/2 19/2
Race
White 20 19
Hispanic 2 2
Asian 1 0
HCV genotype
11 8 1 4
23 2
32 5
Duration of infection (y) 22.1 ± 6.03 22.9 ± 6.68
ALT (IU/mL) 101.7 ± 61.64a 129.8 ± 69.19b
METAVIR Activity 1 (0–3)c 2 (0–3)d
HCV RNA (log10 copies/mL) 6.53 ± 0.39 6.43 ± 0.43
Results shown as mean ± standard deviation, number, or median (range); ALT, alanine aminotransferase; HCV, hepatitis C virus; METAVIR Activity, 
histological score of necroinflammation based on interface, lobular, and portal inflammation. a vs. b, p = 0.16; c vs. d, p = 0.07Journal of Translational Medicine 2007, 5:33 http://www.translational-medicine.com/content/5/1/33
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While haptoglobin, A2M, and ApoA1 are well-established
markers of hepatic fibrosis, SRBP, complement C4A, and
ApoA4 are potentially novel biomarkers of disease.
Protein variants
As well as offering a route to detecting subtle changes in
protein structure, including post translational modifica-
tions, two-dimensional polyacrylamide gel electrophore-
sis enables observation of events such as protein
processing and variations in gene splicing. For a number
of proteins studied in this analysis, the electrophoretic
migration and the peptide mass spectra used to assign
protein identity provide insight into the nature of the
individual protein variant on the gels.
α2 macroglobulin
In this study, the migration of the spot was inconsistent
with the presence of intact A2M (163.1 kDa) molecule.
The peptides identified by mass spectrometry, which were
also used to assign identity, are exclusively derived from
the N-terminal half of the molecule, suggesting increased
processing of the intact molecule may be occurring in the
advanced disease state (see addtional file 1).
Complement C4 precursor
Complement C4 (192.6 kDa, pI 6.65) is a central compo-
nent of the classical complement pathway. Like A2M, the
position of the protein spot on the gels (~30 kDa, pI~8) is
inconsistent with migration of intact protein. Prior to
secretion, the intact molecule is cleaved into distinct α, β,
and γ chains. To identify this protein, 3 peptides were
mapped back to the database sequence using mass spec-
trometry, and all of them were located in the C-terminal,
γ chain region, suggesting that in advanced disease net
production of this subunit is downregulated (addtional
file 1, part b).
Apolipoprotein A-IV
ApoA4 was identified in 2 spots that appeared to be
downregulated in the advanced fibrosis patients. The loca-
tion of 1 of these variants is consistent with migration of
the intact molecule, whereas the second more basic,
smaller form suggests differential processing of ApoA4 in
advanced disease (addtional file 1, part c). Downregula-
tion of ApoA4 has been reported at the gene level in a
thioacetamide-induced rat model of hepatic fibrosis [17].
At the protein level, a small acidic fragment of the protein
Principal Components Analysis (PCA) of Two-dimensional Polyacrylamide Gel Electrophoresis Data Figure 1
Principal Components Analysis (PCA) of Two-dimensional Polyacrylamide Gel Electrophoresis Data. Gel images were proc-
essed using a commercially available analysis package followed by export into Microsoft Excel, normalization, log transforma-
tion, and PCA using Simca P+.
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Spot Selection and Two-dimensional Map of Putative biomarkers Figure 2
Spot Selection and Two-dimensional Map of Putative biomarkers. (a) Image analysis output from Progenesis showing the rela-
tive volume (pixel intensity * mm2) of smaller variant of ApoA4 (spot 846) across all experimental gels. Gel 52 was excluded 
from analysis due to aberrant isoelectric focusing. (b) Image of 2D PAGE showing positions of putative markers. The direction 
of change (advanced relative to moderate disease) is indicated by the white arrows, and the asterisk signifies proteins whose 
behavior is consistent with the commercially available FibroTest. Expression of albumin reflects fragments not adsorbed by 
affinity-based mimetic ligands.
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was detected in the serum of individuals with hepatitis B
infection [18]. Although the fragment was distinct from
the variants described here, it was down-regulated in
infected individuals and could be correlated with necroin-
flammatory scores.
SRBP and ApoA1
One spot identified with altered expression contained 2
proteins, SRBP and ApoA1. Downregulation of ApoA1 is
known to correlate with disease progression, and the spot
was close to the documented location of ApoA1 but was
also consistent with migration of SRBP [19,20]. As the
mass spectrometric approach used for protein identifica-
tion in this study did not enable quantification of individ-
ual proteins in gel spots, it is not possible to say which of
these proteins has contributed to the alteration in inten-
sity without orthogonal validation studies.
Monitoring fibrosis progression
While this was an exploratory study with a small number
of patients, the identified protein isoforms associated
with fibrosis offer insight into the pathology of fibrosis
and provide possibilities for new and more selective bio-
assays. Despite the small sample size, the identification of
haptoglobin, A2M, and ApoA1 in this study provides val-
idation for the proprietary FibroTest (BioPredictive, Paris,
France), which is available in several countries as a non-
invasive alternative to biopsy [21]. Although low serum
haptoglobin may be seen in advanced cirrhosis and
hemolysis, increased expression of haptoglobin in these
patients likely reflects its role as an acute phase reactant to
an inflammatory disease in our cohort of patients with
preserved hepatic function. As albumin detection could
have been affected by impaired hepatic synthetic function
in decompensated cirrhotic disease, such patients were
excluded in this study. Several other specific extracellular
matrix markers, including hyaluronic acid [22-24], tissue
inhibitor of metalloproteinases-1 (TIMP-1) [23,24],
matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, and
procollagen type III N-terminal peptide (PIIINP) [22,23]
have also recently been identified as noninvasive markers
of fibrosis. Further studies are underway to explore
whether these newer markers can be validated as predic-
tive in larger cohorts of patients, and to assess their utility
in following changes in fibrosis over time. However, a sig-
nificant limitation of current serum fibrosis markers is
their ability to only differentiate between mild and
advanced disease and not individual fibrosis stages. This
relates in part to the limited accuracy of a liver biopsy for
the diagnosis of individual fibrosis stage that may be due
to inherent issues with sampling error for non-homoge-
nously distributed disease, and observer differences in
biopsy interpretation. These limitations in our "gold
standard" may also reduce our ability to develop more
accurate predictive biomarkers.
A limitation of our exploratory study was the absence of
comparative protein expression profiles from healthy con-
trol sera or other chronic liver diseases. However, our aim
was to answer a relatively simple, clinically relevant ques-
tion using this open proteomics platform; the ability to
differentiate advanced from mild stage disease in a cohort
of hepatitis C patients matched for host and viral factors
that could influence fibrosis progression. Secondary stud-
ies of validated biomarkers using robust platforms may be
able to evaluate differential protein expression between
fibrosis stages or other chronic liver disease. Any future
diagnostics would need to be optimized for reproducibil-
ity and ease of use. Cost and availability of an assay would
also affect clinical utility. In addition, the study of pro-
teomics has inherent limitations. Several gel and non-gel-
based multidimensional separation methods to explore
the peptidome can be utilized. The 2-D gel methodology
in this study is labor intensive, has a lower detection limit
of 12 kDa., and is unable to differentiate hydrophobic or
low abundance proteins. However, it represents an estab-
lished and rapid method for targeting differential protein
expression. Although matrix-assisted (MALDI) and sur-
face-enhanced laser desorption/ionization (SELDI) mass
spectrometry techniques are relatively newer approaches
for protein detection, highly sensitive, and useful for com-
plex biological samples, there are inherent issues with
sample preparation and reproducibility [25]. Also, pro-
teins are not directly visualized with chromatographic
retentate methods such as SELDI, and instead rely on mul-
tifactorial bioinformatics for peak comparisons and data
analysis. Future diagnostics could incorporate metabo-
lomic changes seen during fibrosis progression as well.
This could potentially improve diagnostic accuracy in
relation to fibrogenesis, provide prognostic information,
and help to integrate targeted non-invasive approaches
into the clinical setting.
Conclusion
Using protein expression profiling of hepatitis C patients,
we identified 7 protein spots that were associated with
fibrosis progression. While 3 of the markers are compo-
nents of the commercially available FibroTest, the remain-
ing 4 may facilitate the development of more sensitive
and specific assays to monitor fibrosis progression.
Abbreviations
Apolipoprotein A-1, ApoA1; apolipoprotein A-IV, ApoA4;
α2-macroglobulin, A2M; Principal Components Analysis,
PCA; serum retinol binding protein, SRBP.
Competing interests
Ian White, William Symonds, Philip Griffin, Nikos
Tsokanas, Mark Skehel, Chiang Liu, Paul Cutler,
Mahanandeeshwar Gattu, and Michelle Berry are current
or former employees of GlaxoSmithKline, which providedJournal of Translational Medicine 2007, 5:33 http://www.translational-medicine.com/content/5/1/33
Page 7 of 8
(page number not for citation purposes)
funding for aspects of this study. Keyur Patel and John
McHutchison have served on advisory boards for and
received research support from GlaxoSmithKline. The GI/
Hepatology Research Division at Duke University Medical
Center has a funded academic alliance with GlaxoSmith-
Kline.
Authors' contributions
IW, PG, NT, and JMS performed electrophoresis, image
analysis, and protein identification; NT, MG, and CL per-
formed the statistical and bioinformatics analysis; IW, KP,
WS, AD, AZ, PC, DR, MB, and JGM were involved in con-
ception and design of the study, selection and coordina-
tion of study samples, and drafting the manuscript; all
authors read and approved the final manuscript.
Additional material
Acknowledgements
Jennifer King, PhD, assisted in preparing the manuscript for publication. The 
project described was supported by Grant Number 1UL1-RR-024128 from 
the National Center for Research Resources (NCRR), a component of the 
National Institutes of Health (NIH) and NIH Roadmap for Medical 
Research. Keyur Patel was supported by the 2004 AASLD Sheila Sherlock 
Clinical and Translational Research Award in Liver Diseases.
References
1. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos
NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraob-
server variation in liver biopsy in patients with chronic HCV
infection.  Am J Gastroenterol 2002, 97:2614-2618.
2. Fanning L, Loane J, Kenny-Walsh E, Sheehan M, Whelton M, Kirwan
W, Collins JK, Shanahan F: Tissue viral load variability in chronic
hepatitis C.  Am J Gastroenterol 2001, 96:3384-3389.
3. Persico M, Palmentieri B, Vecchione R, Torella R, de Sio I: Diagnosis
of chronic liver disease: reproducibility and validation of liver
biopsy.  Am J Gastroenterol 2002, 97:491-492.
4. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F: Sampling var-
iability on percutaneous liver biopsy in patients with chronic
hepatitis C virus infection.  Scand J Gastroenterol 2003,
38:427-432.
5. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre
JP, Cales P, Hepatitis Network 49: Sources of variability in histo-
logical scoring of chronic viral hepatitis.  Hepatology 2005,
41:257-264.
6. Rockey DC, Bissell DM: Noninvasive measures of liver fibrosis.
Hepatology 2006, 43:S113-S120.
7. Thuluvath PJ, Krok KL: Noninvasive markers of fibrosis for lon-
gitudinal assessment of fibrosis in chronic liver disease: are
they ready for prime time?  Am J Gastroenterol 2005,
100:1981-1983.
8. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F,
Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R: Tran-
sient elastography: a new noninvasive method for assess-
ment of hepatic fibrosis.  Ultrasound Med Biol 2003, 29:1705-1713.
9. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M,
Darriet M, Couzigou P, De Ledinghen V: Prospective comparison
of transient elastography, Fibrotest, APRI, and liver biopsy
for the assessment of fibrosis in chronic hepatitis C.  Gastroen-
terology 2005, 128:343-350.
10. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de
Ledinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M:
Noninvasive assessment of liver fibrosis by measurement of
stiffness in patients with chronic hepatitis C.  Hepatology 2005,
41:48-54.
11. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F,
Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V,
Poynard T: A prospective analysis of the prognostic value of
biomarkers (FibroTest) in patients with chronic hepatitis C.
Clin Chem 2006, 52:1887-1896.
12. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber
R, Weiss W: The current state of two-dimensional electro-
phoresis with immobilized pH gradients.  Electrophoresis 2000,
21:1037-1053.
13. Erikson L, Johansson E, Kettaneh-Wold N, Wold S: Introduction to
Multi- and Megavariate Data Analysis Using Projection Methods (PCA &
PLS) Umea, Sweden: Umetrics AB; 1999. 
14. Wood J, White IR, Cutler P: A likelihood-based approach to
defining statistical significance in proteomic analysis where
missing data cannot be disregarded.  Signal Processing 2004,
84:1777-1788.
15. Ostrowski LE, Blackburn K, Radde KM, Moyer MB, Schlatzer DM,
Moseley A, Boucher RC: A proteomic analysis of human cilia:
identification of novel components.  Mol Cell Proteomics 2002,
1:451-465.
16. Perkins DN, Pappin DJ, Creasy DM, Cotterell JS: Probability-based
protein identification by searching sequence databases using
mass spectrometry data.  Electrophoresis 1999, 20:3551-3567.
17. Utsunomiya T, Okamoto M, Hashimoto M, Yoshinaga K, Shiraishi T,
Tanaka F, Mimori K, Inoue H, Watanabe G, Barnard GF, Mori M: A
gene-expression signature can quantify the degree of hepatic
fibrosis in the rat.  J Hepatol 2004, 41:399-406.
18. He QY, Lau GK, Zhou Y, Yuen ST, Lin MC, Kung HF, Chiu JF: Serum
biomarkers of hepatitis B virus infected liver inflammation:
a proteomic study.  Proteomics 2003, 3:666-674.
19. Quero C, Colome N, Prieto MR, Carrascal M, Posada M, Gelpi E,
Abian J: Determination of protein markers in human serum:
Analysis of protein expression in toxic oil syndrome studies.
Proteomics 2004, 4:303-315.
20. Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY, Kwak
YG: The comparative analysis of serum proteomes for the
discovery of biomarkers for acute myeloid leukemia.  Exp
Hematol 2004, 32:836-842.
21. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP,
Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Over-
view of the diagnostic value of biochemical markers of liver
fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest)
in patients with chronic hepatitis C.  Comp Hepatol 2004, 3:8.
22. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D,
Hubscher S, Roskams T, Pinzani M, Arthur MJ: Serum markers
detect the presence of liver fibrosis: a cohort study.  Gastroen-
terology 2004, 127:1704-1713.
23. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel
F, Zarski JP: Circulating matrix metalloproteinases 1, 2, 9 and
their inhibitors TIMP-1 and TIMP-2 as serum markers of
liver fibrosis in patients with chronic hepatitis C: comparison
with PIIINP and hyaluronic acid.  Am J Gastroenterol 2004,
99:271-279.
24. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlot-
sky JM, McHutchison JG: Evaluation of a panel of non-invasive
serum markers to differentiate mild from moderate-to-
advanced liver fibrosis in chronic hepatitis C patients.  J Hepa-
tol 2004, 41:935-942.
Additional file 1
Protein variants for α2macroglobulin, apolipoprotein A-IV, and Comple-
ment C4A. Peptides identified by LC-MS/MS, which were successfully 
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